BlossomHill Therapeutics

BlossomHill Therapeutics designs and develops small molecule medicines aimed at treating cancer and certain autoimmune diseases through targeted biological mechanisms. The company advances clinical programs that include macrocyclic inhibitors directed at specific genetic drivers of cancers such as EGFR- and HER2-mutated non-small cell lung cancer and inhibitors that modulate RNA splicing pathways in hematological malignancies. Its activities encompass drug discovery, chemical design, and execution of early-stage clinical trials that assess safety, pharmacology and potential therapeutic effects. BlossomHill Therapeutics works with scientific and clinical teams to evaluate experimental outcomes and refine molecule profiles for progression through clinical study stages. The company also publishes findings from ongoing trials and presents research data to scientific audiences to support understanding of its therapeutic candidates.

Domain

bhtherapeutics.com

Country

United States

Industry

Biopharma

Employees

11-50

Last Funding

$84.0M

Founded

2019